On December 3, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO (Free ESMO Whitepaper) Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mini-oral presentation details:
Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in Previously Treated NSCLC with
EGFR Atypical Mutations: Randomized Dose Optimization and
CNS Activity
Presentation Number: LBA15
Session Type and Title: Mini Oral session 1: Thoracic malignancies
Lecture Date and Time: Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT
Proffered paper oral presentation details:
Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC:
Randomized Dose Optimization and CNS Activity
Presentation Number: LBA13
Session Type and Title: Proffered Paper session: Thoracic malignancies
Lecture Date and Time: Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT
Full late-breaking abstracts are available for public viewing via the ESMO (Free ESMO Whitepaper) Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO (Free ESMO Whitepaper) Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
(Press release, ORIC Pharmaceuticals, DEC 3, 2025, View Source [SID1234661105])